Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

gen received an option to obtain an exclusive license to Cytokinetics' cardiac contractility program, (including the lead drug candidate, CK-1827452). Under the terms of the agreement, Cytokinetics is eligible to receive pre-commercialization and commercialization milestone payments of up to $600 million on CK-1827452 and other products arising from the collaboration, and royalties that escalate based on increasing levels of annual net sales of products commercialized under the agreement. Cytokinetics also has the opportunity to earn increased royalties by sharing certain Phase 3 development costs. In that case, Cytokinetics could co-promote products in North America and would have an agreed role in commercialization activities in North America. The collaboration is worldwide, excluding Japan.

Development Status of CK-1827452

CK-1827452, a novel cardiac myosin activator, has been the subject of a clinical trials program comprised of multiple Phase 1 and Phase 2a trials. This program was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetic profile of both intravenous and oral formulations of CK-1827452 for the potential treatment of heart failure across the continuum of care, in both hospital and outpatient settings. Two Phase 2a clinical trials of CK-1827452 from this program have been completed, and two Phase 2a clinical trials of CK-1827452 are ongoing.

The first Phase 2a clinical trial evaluated CK-1827452 in patients with stable heart failure. Data from that trial were recently presented at the American College of Cardiology Meeting in March 2009. Cytokinetics plans to present additional analyses from this trial at a Late Breaking Trial session at the 2009 Heart Failure Congress of the European Society of Cardiology, to be held from May 30 - June 2 in Nice, France. The second Phase 2a clinical trial was designed to evaluate an intravenous formulation together with an oral fo
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Sales Horizons, a leader in sales ... training course – Mastering the Complex Sale ... Drawn from proven sales training programs used by thousands ... Sale online sales training course is available to every ... contact with customers, like technical support, engineers, clinical support, ...
(Date:7/30/2014)... 2014 A study presented at the ... efficacy of CSL Behring,s C1 Inhibitor (C1-INH) concentrate ... highly sensitized patients. C1-INH is a human protein ... The study shows that post-transplant treatment ... levels of complement components 3 and 4, suggesting ...
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... Vycom announces the addition of Thermax ... meet Factory Mutual (FM) 4910 fire propagation and smoke ... benches, process tools, fume hoods, furniture and cabinetry. These ... semiconductor wafers used in electronic chip manufacturing. , ... with excellent workability and superior aesthetics. It is available ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2
... of articles on developing start-up companies in the technology or ... - You've started your new company, named it, and perhaps ... need additional funding, what other choices do you have? Before ... , ,Most of us recognize that we must have ...
... fast becoming one of the most sought-after spokesmen on behalf ... chief information officers and others will have plenty of prospective ... staff openings. , ,Tim Jump, who will speak at ... in Milwaukee, is a pre-engineering teacher by trade, and ...
... CDW Corp . has signed a definitive merger agreement ... equity firm Madison Dearborn Partners , which has endorsed ... a conference call with investors, CDW chief executive officer John ... growth strategies, including a planned expansion of the Berbee platform. ...
Cached Biology Technology:Early Stage: Step 11 - Other forms of finance 2Early Stage: Step 11 - Other forms of finance 3Early Stage: Step 11 - Other forms of finance 4Jump starting technology education 2Jump starting technology education 3CDW buyer supports Berbee growth plans 2
(Date:7/30/2014)... the way for a breakthrough that may prevent ... to poisonous chemicalsparticularly those in pesticides and chemical ... issue of the journal ChemBioChem outlines ... commonly used in pesticides and warfare agents. The ... Engineering Associate Professor of Chemical and Biological Engineering ...
(Date:7/30/2014)... truffle uses reversible epigenetic processes to regulate its genes, ... - a picture of the genome regulation taking place ... journal Genome Biology and illustrates how the ... ,jumping genes,. The authors say this may shed light ... , Black truffles (Tuber melanosporum), also known as Prigord ...
(Date:7/30/2014)... Red Queen in Lewis Carroll,s Through the Looking ... National University of Singapore improved a 35-year-old ecology ... decades to millions of years. , The new ... incorporates the "Red Queen Effect," an evolutionary hypothesis ... which suggests that organisms must constantly increase their ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3
... virus previously used as a marker in tracing human ... State. Results of this study also suggest that some ... than previously thought. , "The most genetically divergent human ... researcher at Penn State's Center for Infectious Disease Dynamics. ...
... Baptist Medical Center and colleagues at four other medical ... identify genes that may contribute to early atherosclerosis. ... and early adult life who have a genetic predisposition ... for heart disease and stroke sooner and more aggressively," ...
... In a new twist on the slogan “milk does ... staple as a contrast agent in gastrointestinal imaging exams—with ... the annual meeting of the Radiological Society of North ... bowel distension and enhancement as we see with the ...
Cached Biology News:Viral marker of human migration suspect 2Scientists work to identify genes that contribute to early heart attack risk 2Got inexpensive contrast agent? Milk plays new role in imaging 2
Rabbit anti-NFkB p105/p50 (Ser337) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
CD69/CD3 50 tests...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Biology Products: